Ovarian tissue cryopreservation for fertility preservation in cancer patients: Successful establishment and feasibility of a multidisciplinary collaboration

Departments of Obstetrics/Gynecology, University of Pennsylvania, 3701 Market Street, Suite 800, Philadelphia, PA 19104, USA.
Journal of Assisted Reproduction and Genetics (Impact Factor: 1.72). 04/2012; 29(6):495-502. DOI: 10.1007/s10815-012-9753-7
Source: PubMed


As advancements in cancer therapies have led to dramatic improvements in long term survival, there has been increasing interest in methods to expand fertility preservation options for cancer patients.
An experimental protocol for ovarian tissue cryopreservation was developed at the University of Pennsylvania for patients requiring gonadotoxic therapies. The protocol for adults was implemented at the Hospital of the University of Pennsylvania and for children at the Children's Hospital of Philadelphia in collaboration with the Oncofertility Consortium and the National Physicians Cooperative (NPC).
A total of twenty-one patients (age range: 8-36 years) have cryopreserved ovarian tissue as part of this study. While patients had a variety of diagnoses and treatment exposures, 10/21 (48 %) patients suffered from hematologic disorders and 43 % were anticipating stem cell transplantation. No patients have requested that the tissue be used for clinical purposes.
Ovarian tissue cryopreservation protocols can be implemented at pediatric and adult institutions through multi-disciplinary collaboration. While more research is needed to determine the safety and efficacy of ovarian tissue cryopreservation, this procedure provides hope for preserving the ability to have biological offspring to patients facing gonadotoxic therapies for a variety of medical conditions.


Available from: Jill P Ginsberg
  • Source
    • "The resected tissue is cut into strips and cryopreserved. Because the process does not require hormonal stimulation it is the only fertility preservation technique that is available to pre-pubertal girls or females in whom initiation of treatment cannot be delayed [50,51]. Following completion of treatment the ovarian tissue can be thawed and transplanted orthotopically, i.e., at the site of the ovaries, or heterotopically, i.e., at another location. "
    Preview · Article · Sep 2014
  • Source
    • "Thus far, at least 30 live births have been reported following cryopreservation and autotransplantation of ovarian tissue.[1] Various methods for ovarian tissue cryopreservation and thawing23456789 are being used worldwide. Although the efficacy of cryopreservation of ovarian tissue may thus differ from one center to another, information regarding these differences is scarce. "
    [Show abstract] [Hide abstract] ABSTRACT: Purpose: To evaluate the effect of cryopreservation and thawing of ovarian tissue from oncological patients opting for fertility preservation on ovarian tissue viability. Methods: In this prospective cohort study, the ovarian tissue viability before and after cryopreservation and thawing was measured for 25 newly diagnosed oncological patients who had their ovarian tissue cryopreserved. Outcome measures were follicle integrity (histology), follicle viability (Calcein viability assay), steroid hormone production (estradiol and progesterone production in vitro) and overall tissue viability (glucose uptake in vitro). This study was conducted at a Cryobank for storage of ovarian tissue in a university hospital. Results: Cryopreserved/thawed ovarian tissue showed a de- creased glucose uptake when compared to tissue that had not been cryopreserved. In addition, a diminished E2 and P4 production was observed after cryopreservation and thawing, despite the fact that numbers of viable follicles as determined by the Calcein viability assay were comparable. Histological examination revealed a higher percentage of degenerated fol- licles after cryopreservation and thawing. Conclusions: Ovarian tissue cryopreservation and thawing im- pairs the viability of ovarian tissue in oncological patients opting for fertility preservation.
    Full-text · Article · Jun 2014 · Journal of Assisted Reproduction and Genetics
  • Source
    [Show abstract] [Hide abstract] ABSTRACT: Breast cancer is the most common tumor in childbearing women. In the last decades, considerable improvement in breast cancer-related death has been achieved with adjuvant therapies (chemotherapy, endocrine and targeted therapies, radiotherapy) but at cost of significant long-term sequels, including infertility. Reproductive issues are of great importance to young women, in particular for those who did not complete their families before breast cancer diagnosis: patients should be adequately informed at the time of diagnosis about the risk of infertility and the available methods for fertility preservation. This review will focus on incidence and impact of infertility secondary to breast cancer treatment, the available options for ovarian function preservation, including embryo and oocyte cryopreservation, ovarian tissue cryopreservation, and ovarian suppression with gonadotropin-releasing hormone agonists. We will also discuss the optimal time of subsequent pregnancy, the potential risks for the mother and the fetus, and the impact of therapies on breastfeeding.
    Preview · Article · Sep 2012 · Maturitas
Show more